Kaaren K Reichard (Kaaren Reichard)

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 8

Top Topics

Multiple Myeloma

Chronic Myeloid Leukemia

Top Venues

Blood cancer journal

This page only lists publications with an associated author ORCID identifier.

Publications

Ayalew Tefferi, Animesh Pardanani, Kebede H Begna, Aref A Al-Kali, William Joseph Hogan, Mark R Litzow, Rhett P Ketterling, Kaaren K Reichard, Naseema Gangat
Calr type 1/like mutation in myelofibrosis is the most prominent predictor of momelotinib drug survival and longevity without transplant. Blood cancer journal 14 (1) (2024)
Mostafa Abdallah, Kaaren K Reichard, Naseema Gangat, Ayalew Tefferi
Treatment-emergent mutations in myelodysplastic syndrome with del(5q) - lenalidomide related or disease-intrinsic clonal evolution? Blood cancer journal 14 (1) (2024)
Ayalew Tefferi, Animesh Pardanani, Kebede H Begna, Aref A Al-Kali, William Joseph Hogan, Mark R Litzow, Rhett P Ketterling, Kaaren K Reichard, Naseema Gangat
Calr type 1/like mutation in myelofibrosis is the most prominent predictor of momelotinib drug survival and longevity without transplant. Blood cancer journal 14 (1) (2024)
Mostafa Abdallah, Kaaren K Reichard, Naseema Gangat, Ayalew Tefferi
Treatment-emergent mutations in myelodysplastic syndrome with del(5q) - lenalidomide related or disease-intrinsic clonal evolution? Blood cancer journal 14 (1) (2024)
Ayalew Tefferi, Animesh Pardanani, Kebede H Begna, Aref A Al-Kali, William Joseph Hogan, Mark R Litzow, Rhett P Ketterling, Kaaren K Reichard, Naseema Gangat
Calr type 1/like mutation in myelofibrosis is the most prominent predictor of momelotinib drug survival and longevity without transplant. Blood cancer journal 14 (1) (2024)
Mostafa Abdallah, Kaaren K Reichard, Naseema Gangat, Ayalew Tefferi
Treatment-emergent mutations in myelodysplastic syndrome with del(5q) - lenalidomide related or disease-intrinsic clonal evolution? Blood cancer journal 14 (1) (2024)
Maymona G Abdelmagid, Aref A Al-Kali, Mark R Litzow, Kebede H Begna, William Joseph Hogan, Mirinal S Patnaik, Shahrukh K. Hashmi, Michelle A Elliott, Hassan B Alkhateeb, Omer S Karrar, Farah Fleti, Mohammed H Elnayir, Candido E Rivera, Hemant S Murthy, James M Foran, Mohamed A Kharfan-Dabaja, Talha Badar, David S Viswanatha, Kaaren K Reichard, Naseema Gangat, Ayalew Tefferi
Real-world experience with ponatinib therapy in chronic phase chronic myeloid leukemia: impact of depth of response on survival and prior exposure to nilotinib on arterial occlusive events. Blood cancer journal 13 (1) (2023)
Kaaren K Reichard, Ayalew Tefferi, Maymona Abdelmagid, Attilio Orazi, Christina Alexandres, Joanna Haack, Patricia T Greipp
Pure (acute) erythroid leukemia: morphology, immunophenotype, cytogenetics, mutations, treatment details, and survival data among 41 Mayo Clinic cases. Blood cancer journal 12 (11) (2022)